Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85983 trials found · Page 63 of 4300
-
Personalized medicine breakthrough: new hope for cystic fibrosis patients with rare mutations
Disease control CompletedCF is caused by mutations in the gene that encodes the 'Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)' channel. To re-establish the function of this complex chloride channel, typically two to three drug modes of action are needed. To date, clinical studies of CFTR mo…
Phase: PHASE2 • Sponsor: Kors van der Ent • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Cannabis extract trial offers hope for untreatable seizures
Disease control Recruiting now1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberou…
Phase: PHASE3 • Sponsor: Oils4Cure • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New injection shows promise in slowing leading cause of blindness
Disease control OngoingThe goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in …
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
Major trial tests new drug for debilitating muscle disease
Disease control OngoingA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Scientists unleash army of sterile mosquitoes to fight deadly viruses
Prevention TerminatedMosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts of the world, yet there are no treatments for them n…
Phase: NA • Sponsor: Michigan State University • Aim: Prevention
Last updated Apr 17, 2026 16:10 UTC
-
New cell therapy trial offers hope when CAR-T fails in leukemia
Disease control Recruiting nowThis is a single-center, double-blind, randomized trial. Patients with relapsed or refractory acute B-lymphoblastic leukemia(r/r B-ALL) experiencing early functional exhaustion of CAR-T cells will be randomly allocated into three groups: the control cell group, the CIK treatment …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New drug trial aims to reverse liver scarring in advanced fatty liver disease
Disease control Recruiting nowThe study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New hope for hard-to-treat lung cancer: targeted combo enters phase 3 trial
Disease control Recruiting nowThis is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC
-
New hope for tough cancers: experimental drugs target key cancer driver
Disease control Recruiting nowThe purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subpro…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
New hope for lung cancer patients: experimental drug takes on chemo after standard therapy fails
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
New brain cancer combo aims to outsmart Tumor's defenses
Disease control Recruiting nowThis phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tum…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests promising drug
Disease control Recruiting nowThis study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
New drug aims to stop debilitating gut infection from coming back
Prevention Recruiting nowThe overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 …
Phase: PHASE3 • Sponsor: Vedanta Biosciences, Inc. • Aim: Prevention
Last updated Mar 12, 2026 13:51 UTC
-
New hope for tough lung cancers: experimental drug takes on chemo
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and pla…
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 24, 2026 16:05 UTC
-
New Two-Drug combo aims to beat hepatitis b
Disease control OngoingThis is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
Phase: NA • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Apr 07, 2026 14:37 UTC
-
New 'Living Drug' trial targets tough stomach and colon cancers
Disease control Recruiting nowThe goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Phase: PHASE1, PHASE2 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Supercharged immune cells aim to prevent leukemia relapse after transplant
Disease control Recruiting nowThis trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
Custom-Made vaccine fights tough uterine cancer in new trial
Disease control Recruiting nowBackground: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. Objective: To test 2 study drugs-a vaccine that targets…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Gene therapy trial offers hope for children with severe epilepsy
Disease control Recruiting nowENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an …
Phase: PHASE1, PHASE2 • Sponsor: Encoded Therapeutics • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
Major study tracks Long-Term safety of Game-Changing HIV prevention shot
Prevention Recruiting nowThe purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Parti…
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Apr 20, 2026 16:16 UTC